China Resources Pharmaceutical Group Valuation

Q: What is the Fair Price of 3320 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

3320 (HK$4.91) is trading below our estimate of [[fair value]] (HK$17.57)

Is 3320 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3320 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

DiscountedCashFlow

Community Contributor

HK$17.57

Fair Value

72.0% undervalued

Number of Analysts

Below Fair Value: 3320 (HK$4.91) is trading below our estimate of fair value (HK$17.57)

Significantly Below Fair Value: 3320 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3320?

Key metric: As 3320 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 3320. This is calculated by dividing 3320's market cap by their current earnings.
What is 3320's PE Ratio?
PE Ratio	10.1x
Earnings	CN¥2.80b
Market Cap	CN¥28.04b

3320 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.5x
Enterprise Value/EBITDA	9.7x
PEG Ratio	0.6x

Price to Earnings Ratio vs Peers

How does 3320's PE Ratio compare to its peers?

The above table shows the PE ratio for 3320 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	18.2x
512 Grand Pharmaceutical Group	13.7x	12.34%	HK$28.6b
3933 United Laboratories International Holdings	7.7x	-0.22%	HK$25.9b
2096 Simcere Pharmaceutical Group	33.6x	24.32%	HK$32.3b
867 China Medical System Holdings	17.9x	14.27%	HK$32.4b
3320 China Resources Pharmaceutical Group	10.1x	16.52%	HK$30.6b

Price-To-Earnings vs Peers: 3320 is good value based on its Price-To-Earnings Ratio (10.1x) compared to the peer average (18.2x).

Price to Earnings Ratio vs Industry

How does 3320's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
2552 Hua Medicine (Shanghai)	2.9x	-89.83%	US$461.47m
858 Extrawell Pharmaceutical Holdings	1x	n/a	US$29.86m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 3320 is good value based on its Price-To-Earnings Ratio (10.1x) compared to the Hong Kong Pharmaceuticals industry average (13.6x).

Price to Earnings Ratio vs Fair Ratio

What is 3320's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3320 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	10.1x
Fair PE Ratio	19.5x

Price-To-Earnings vs Fair Ratio: 3320 is good value based on its Price-To-Earnings Ratio (10.1x) compared to the estimated Fair Price-To-Earnings Ratio (19.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 3320 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	HK$4.91	HK$6.80 +38.49%	12.71%	HK$8.80	HK$5.60	n/a	11
Oct ’26	HK$4.81	HK$6.65 +38.33%	13.01%	HK$8.80	HK$5.60	n/a	13
Sep ’26	HK$4.91	HK$6.68 +35.99%	12.60%	HK$8.80	HK$5.70	n/a	13
Aug ’26	HK$5.35	HK$6.78 +26.67%	13.30%	HK$8.81	HK$5.80	n/a	11
Jul ’26	HK$5.12	HK$6.78 +32.36%	12.75%	HK$8.61	HK$5.80	n/a	11
Jun ’26	HK$5.15	HK$6.78 +31.59%	12.75%	HK$8.61	HK$5.80	n/a	11
May ’26	HK$4.90	HK$6.82 +39.23%	13.01%	HK$8.61	HK$5.80	n/a	11
Apr ’26	HK$5.19	HK$7.06 +36.07%	13.58%	HK$8.80	HK$5.80	n/a	12
Mar ’26	HK$5.30	HK$7.21 +36.09%	14.94%	HK$9.60	HK$5.80	n/a	12
Feb ’26	HK$5.23	HK$7.21 +37.91%	14.94%	HK$9.60	HK$5.80	n/a	12
Jan ’26	HK$5.70	HK$7.13 +25.12%	16.73%	HK$9.90	HK$5.80	n/a	11
Dec ’25	HK$5.25	HK$7.13 +35.85%	16.73%	HK$9.90	HK$5.80	n/a	11
Nov ’25	HK$5.54	HK$7.32 +32.15%	17.52%	HK$9.90	HK$5.80	n/a	12
Oct ’25	HK$6.01	HK$7.09 +17.91%	15.02%	HK$9.30	HK$5.80	HK$4.81	11
Sep ’25	HK$5.50	HK$7.40 +34.45%	14.49%	HK$9.30	HK$5.80	HK$4.91	10
Aug ’25	HK$5.26	HK$7.36 +39.90%	14.94%	HK$9.30	HK$5.82	HK$5.35	10
Jul ’25	HK$5.79	HK$7.38 +27.50%	14.66%	HK$9.30	HK$5.82	HK$5.12	10
Jun ’25	HK$5.79	HK$7.38 +27.50%	14.66%	HK$9.30	HK$5.82	HK$5.15	10
May ’25	HK$5.08	HK$7.41 +45.78%	15.48%	HK$9.30	HK$5.82	HK$4.90	9
Apr ’25	HK$5.00	HK$7.58 +51.58%	13.90%	HK$9.30	HK$6.20	HK$5.19	8
Mar ’25	HK$5.25	HK$7.72 +47.00%	13.84%	HK$9.30	HK$5.94	HK$5.30	8
Feb ’25	HK$4.83	HK$7.94 +64.42%	12.54%	HK$9.30	HK$5.94	HK$5.23	8
Jan ’25	HK$5.13	HK$7.94 +54.80%	12.54%	HK$9.30	HK$5.94	HK$5.70	8
Dec ’24	HK$4.85	HK$7.94 +63.74%	12.54%	HK$9.30	HK$5.94	HK$5.25	8
Nov ’24	HK$4.94	HK$8.00 +62.02%	13.62%	HK$9.80	HK$5.94	HK$5.54	8
Oct ’24	HK$5.20	HK$7.91 +52.10%	13.32%	HK$9.80	HK$6.40	HK$6.01	9

AnalystPriceTarget

Community Contributor

HK$6.8

Fair Value

27.8% undervalued

Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/23 15:36
End of Day Share Price	2025/10/23 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

China Resources Pharmaceutical Group Limited is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bo Li	BofA Global Research
Zhishun Siu	CCB International Securities Limited
Jing Qiang	China International Capital Corporation Limited